186 related articles for article (PubMed ID: 11959574)
1. DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.
Schinazi RF; Mellors J; Bazmi H; Diamond S; Garber S; Gallagher K; Geleziunas R; Klabe R; Pierce M; Rayner M; Wu JT; Zhang H; Hammond J; Bacheler L; Manion DJ; Otto MJ; Stuyver L; Trainor G; Liotta DC; Erickson-Viitanen S
Antimicrob Agents Chemother; 2002 May; 46(5):1394-401. PubMed ID: 11959574
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
[TBL] [Abstract][Full Text] [Related]
3. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
[TBL] [Abstract][Full Text] [Related]
4. Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV.
Erickson-Viitanen S; Wu JT; Shi G; Unger S; King RW; Fish B; Klabe R; Geleziunas R; Gallagher K; Otto MJ; Schinazi RF
Antivir Chem Chemother; 2003 Jan; 14(1):39-47. PubMed ID: 12790515
[TBL] [Abstract][Full Text] [Related]
5. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.
Anderson KS
Biochim Biophys Acta; 2002 Jul; 1587(2-3):296-9. PubMed ID: 12084471
[TBL] [Abstract][Full Text] [Related]
6. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
7. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
8. Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine.
Hernandez-Santiago BI; Mathew JS; Rapp KL; Grier JP; Schinazi RF
Antimicrob Agents Chemother; 2007 Jun; 51(6):2130-5. PubMed ID: 17403996
[TBL] [Abstract][Full Text] [Related]
9. l-2',3'-Didehydro-2',3'-dideoxy-3'-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance.
Chong Y; Gumina G; Mathew JS; Schinazi RF; Chu CK
J Med Chem; 2003 Jul; 46(15):3245-56. PubMed ID: 12852755
[TBL] [Abstract][Full Text] [Related]
10. In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine.
Hammond JL; Parikh UM; Koontz DL; Schlueter-Wirtz S; Chu CK; Bazmi HZ; Schinazi RF; Mellors JW
Antimicrob Agents Chemother; 2005 Sep; 49(9):3930-2. PubMed ID: 16127074
[TBL] [Abstract][Full Text] [Related]
11. Nanogel-Conjugated Reverse Transcriptase Inhibitors and Their Combinations as Novel Antiviral Agents with Increased Efficacy against HIV-1 Infection.
Senanayake TH; Gorantla S; Makarov E; Lu Y; Warren G; Vinogradov SV
Mol Pharm; 2015 Dec; 12(12):4226-36. PubMed ID: 26565115
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype.
Van Laethem K; Witvrouw M; Pannecouque C; Van Remoortel B; Schmit JC; Esnouf R; Kleim JP; Balzarini J; Desmyter J; De Clercq E; Vandamme AM
AIDS; 2001 Mar; 15(5):553-61. PubMed ID: 11316991
[TBL] [Abstract][Full Text] [Related]
14. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Stürmer M; Staszewski S; Doerr HW
Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.
Shi J; McAtee JJ; Schlueter Wirtz S; Tharnish P; Juodawlkis A; Liotta DC; Schinazi RF
J Med Chem; 1999 Mar; 42(5):859-67. PubMed ID: 10072683
[TBL] [Abstract][Full Text] [Related]
16. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).
Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP
Biochem Pharmacol; 1998 Mar; 55(5):617-25. PubMed ID: 9515572
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
Dutschman GE; Bridges EG; Liu SH; Gullen E; Guo X; Kukhanova M; Cheng YC
Antimicrob Agents Chemother; 1998 Jul; 42(7):1799-804. PubMed ID: 9661024
[TBL] [Abstract][Full Text] [Related]
19. Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies.
Mansky LM; Pearl DK; Gajary LC
J Virol; 2002 Sep; 76(18):9253-9. PubMed ID: 12186909
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
Reinis M; Vandasová J; Stanková M; Linka M; Brůcková M
Acta Virol; 2001; 45(5-6):279-86. PubMed ID: 12083326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
